Arcus Biosciences Inc. priced its IPO of 8 million common shares at $15 apiece.
The Hayward, Calif.-based company expects total gross proceeds of about $120 million. The company also granted underwriters an option to buy an additional 1.2 million common shares.
In a separate filing, Arcus Biosciences registered an additional 1,035,000 shares, also priced $15 apiece. The shares will bring the offering size up to 9.2 million shares, and raise additional gross proceeds of about $15.5 million.
The company's shares are expected to begin trading on the NYSE under the symbol RCUS on March 15.
The offering is expected to close March 19.
Citigroup, Goldman Sachs & Co. LLC and Leerink Partners are acting as joint book-running managers for the offering.
Arcus Biosciences is a clinical-stage biopharmaceutical company, which engages in developing and commercializing cancer immunotherapies in the U.S.
